Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | ATM | Q13315 | 1/20 | 0.33 |
| ▸ | BAZ2B | Q9UIF8 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.31 |
| ▸ | HRH1 | P35367 | 1/20 | 0.31 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL294331 | 0.81 | KDM4E (0.35) | KDM4EALDH1A1SMN1; SMN2HSP90AA1LMNA | |
| SCHEMBL13397712 | 0.79 | KDM4E (0.34) | KDM4EALDH1A1SMN1; SMN2HSP90AA1LMNA | |
| SCHEMBL8427620 | 0.79 | LMNA (0.37) | KDM4EALDH1A1SMN1; SMN2HSP90AA1LMNA | |
| SCHEMBL3026028 | 0.76 | — | — | |
| SCHEMBL681871 | 0.75 | — | — | |
| SCHEMBL29738290 | 0.75 | — | — | |
| SCHEMBL20738688 | 0.71 | — | — | |
| SCHEMBL20733950 | 0.71 | — | — | |
| SCHEMBL978914 | 0.71 | — | — | |
| SCHEMBL21515931 | 0.71 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10836755-B2 | Cardiac sarcomere inhibitors | CYTOKINETICS, INC. (US) | 2020-11-17 | — | — | US | disclosed |
| US-20190256504-A1 | CARDIAC SARCOMERE INHIBITORS | CYTOKINETICS, INC. | 2019-08-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10836755-B2 | Cardiac sarcomere inhibitors | TNNI3, TNNT2, MYLK2 | KDM4E 3210/4885ALDH1A1 3390/4885SMN1; SMN2 156/4885 |
| US-20190256504-A1 | CARDIAC SARCOMERE INHIBITORS | TNNI3, TNNT2, MYLK2 | KDM4E 3210/4885ALDH1A1 3390/4885SMN1; SMN2 156/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.